- 作者: Monika Kumari, Shih-Chieh Su, Kang-Hao Liang, Hsiu-Ting Lin, Yu-Feng Lu, Kai-Chi Chen, Wan-Yu Chen & Han-Chung Wu
- 作者服務機構: 1.Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan 2.Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan
- 中文摘要:
- 英文摘要:
Background Sequential infections with SARS-CoV-2 variants such as Alpha, Delta, Omicron and its sublineages may
cause high morbidity, so it is necessary to develop vaccines that can protect against both wild-type (WT) virus and its
variants. Mutations in SARS-CoV-2’s spike protein can easily alter viral transmission and vaccination efectiveness.
Methods In this study, we designed full-length spike mRNAs for WT, Alpha, Delta, and BA.5 variants and integrated
each into monovalent or bivalent mRNA-lipid nanoparticle vaccines. A pseudovirus neutralization assay was con‑
ducted on immunized mouse sera in order to examine the neutralizing potential of each vaccine.
Results Monovalent mRNA vaccines were only efective against the same type of virus. Interestingly, monovalent
BA.5 vaccination could neutralize BF.7 and BQ.1.1. Moreover, WT, Alpha, Delta, BA.5, and BF.7 pseudoviruses were
broadly neutralized by bivalent mRNA vaccinations, such as BA.5+WT, BA.5+Alpha, and BA.5+Delta. In particular,
BA.5+WT exhibited high neutralization against most variants of concern (VOCs) in a pseudovirus neutralization assay.
Conclusions Our results show that combining two mRNA sequences may be an efective way to develop a broadly
protective SARS-CoV-2 vaccine against a wide range of variant types. Importantly, we provide the optimal combina‑
tion regimen and propose a strategy that may prove useful in combating future VOCs. - 中文關鍵字:
- 英文關鍵字: SARS-CoV-2, Variants of concern (VOCs), Bivalent mRNA vaccines, Vaccine efcacy